US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.
The US Centers for Medicare and Medicaid Services is interested in "serious discussions" about new payment models for one-time curative treatments but is wary of arrangements that might lead to higher list prices, such as by including rebates tied to outcomes, CMS administrator Seema Verma told reporters at a 22 May meeting.
“We’ve heard a lot of discussion around value-based [contracts] and companies are coming to us and saying, ‘Hey, can [CMS]...
The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.
The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
